Rifampicin Breadcrumb Home Glossary Rifampicin Short description Rifampicin is an antibiotic especially used to treat mycobacterial infections. Detailed description Rifampicin inhibits the RNA polymerase – a bacterial enzyme needed for protein production. More about “Rifampicin” Jul 2023 Liver Int Rifaximin may induce rifampicin resistance in coagulase-negative staphylococci Autoren Schulte LM et al. Nov 2022 Eur Respir J Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany Autoren Otto-Knapp R et al. Please use this image only in connection with this press release. © scienceRELATIONS Feb 20 2023 Antibiotics resistance: Tuberculosis therapy at the limit? The development of antibiotic resistance is increasingly complicating the treatment of tuberculosis. Patients suffering from multidrug-resistant tuberculosis (MDR-TB) are particularly hard hit. In Jul 2022 Antibiotics The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus Autoren Balansky J et al. Mar 2022 J Infect Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study Autoren Tunesi S et al. Sep 2016 Clin Microbiol Infect Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria Autoren Andre E et al. Jan 2015 J Antimicrob Chemother Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients Autoren Heinrich N et al. Sep 2021 BMC Infect Dis Transmission patterns of rifampicin resistant Mycobacterium tuberculosis complex strains in Cameroon: a genomic epidemiological study Autoren Merker M et al. Mar 2021 Antimicrob Agents Chemother Thin layer agar-based direct phenotypic drug-susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance, otherwise missed by WHO endorsed diagnostic tests Autoren Ardizzoni E et al. Feb 2021 Eur Respir J Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(-1) rifampicin Autoren Te Brake LHM et al. Pagination Previous page ‹‹ Seite 1 Current page 2 Seite 3 Seite 4 Seite 1 Seite 2 Seite 3 Seite 4 Next page ››
Jul 2023 Liver Int Rifaximin may induce rifampicin resistance in coagulase-negative staphylococci Autoren Schulte LM et al.
Nov 2022 Eur Respir J Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany Autoren Otto-Knapp R et al.
Jul 2022 Antibiotics The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus Autoren Balansky J et al.
Mar 2022 J Infect Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study Autoren Tunesi S et al.
Sep 2016 Clin Microbiol Infect Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria Autoren Andre E et al.
Jan 2015 J Antimicrob Chemother Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients Autoren Heinrich N et al.
Sep 2021 BMC Infect Dis Transmission patterns of rifampicin resistant Mycobacterium tuberculosis complex strains in Cameroon: a genomic epidemiological study Autoren Merker M et al.
Mar 2021 Antimicrob Agents Chemother Thin layer agar-based direct phenotypic drug-susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance, otherwise missed by WHO endorsed diagnostic tests Autoren Ardizzoni E et al.
Feb 2021 Eur Respir J Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(-1) rifampicin Autoren Te Brake LHM et al.
